Janssen's hepatitis C drug gets FDA panel endorsement

10/25/2013 | Medscape (free registration) · PharmaTimes (U.K.)

An FDA panel endorsed the approval of Janssen's simeprevir to be used in combination with peginterferon alfa and ribavirin to treat chronic hepatitis C in treatment-naive adults with compensated liver disease. The therapy is also intended for patients who did not respond to previous interferon treatment.

View Full Article in:

Medscape (free registration) · PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX